Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NOUS PEV

Next Previous
Search
Drug Profile

NOUS PEV

Alternative Names: NOUS 100 PV; NOUS-PEV; Personalised cancer neoantigen genetic vaccine - Nouscom; personalised cancer neoantigen vaccine - Nouscom

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nouscom
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma; Non-small cell lung cancer
  • No development reported Urogenital cancer

Most Recent Events

  • 04 Apr 2025 NOUS PEV is still in phase-I trial in Malignant-melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Belgium (IM), phase-I development in Non-small-cell-lung-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Belgium (IM), United Kingdom (IM), Spain (IM) (NCT04990479)
  • 05 Mar 2025 Nouscom SRL terminates phase I trial in Malignant-melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Belgium (IM), phase-I development in Non-small-cell-lung-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Belgium (IM), United Kingdom (IM), Spain due to sponsor's decision (IM) (NCT04990479)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in Spain (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top